The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Pfizer is facing a sharp revenue decline, with Comirnaty vaccine revenue dropping from over $37 billion in 2022 to below $10 billion by 2025. In response to this slump in vaccine sales, Pfizer is pivoting towards oncology acquisitions to offset the decline.